Thus, in future clinical trials, CCDC6 protein expression and distribution should be assayed by IHC analysis in addition to the molecular screen of DDR genes defects and to an accurate estimate of the HRD, in order to select NSCLC patients that could benefit of radio and chemotherapy when combined with PARP inhibitors [64,65,66]. The gene discussed is CCDC6; the disease is non-small cell lung carcinoma.